SomaSenguptaMD

Neurology • Chapel Hill, NC

Neurooncology

Professor

Join to view full profile

Dr. Sengupta is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sengupta's full profile

Already have an account?

Office
University of North Carolina, Chapel Hill
Chapel Hill, NC 27599

Summary

Dr. Soma Sengupta is a neuro-oncologist and clinical trialist at the University of North Carolina, Chapel Hill. She received her medical degree from University of Cambridge School of Medicine and has been in practice 20 years. She also speaks multiple languages, including French and Bengali. She specializes in neurooncology and is experienced in neuro-oncology and brain tumor survivorship.

Humanizing Brain Tumors - Five To Thrive Live

The courage, resilience and determination of people diagnosed with brain tumors inspires all of us to celebrate our humanity, our lives and our connections. On

Interview with Dr. Soma Sengupta: Advances in Glioblastoma Multiforme (GBM) by C

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Soma Sengupta, the Harold C. Schott Endowed Brain Tumor Molecular Therapeutics

Education & Training

Beth Israel Deaconess Medical Center/Harvard Medical SchoolResidency, Neurology, 2008 - 2011
Johns Hopkins UniversityResidency, Internal Medicine, 2007 - 2008
University of Cambridge School of MedicineClass of 2000

Certifications & Licensure

OH State Medical License 2019 - 2026
NC State Medical License 2023 - 2025
KY State Medical License 2021 - 2024
GA State Medical License 2016 - 2019
MA State Medical License 2011 - 2016
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Leonard Tow Humanism Award Gold Humanism Honor Society, 2023
Joslin Haggart Yeiser Unsung Hero Award Cancer Family Care, 2022

Clinical Trials

Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma Start of enrollment: 2018 May 20
Completed
Phase 3
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Start of enrollment: 2019 Sep 29
Active, not recruiting
Phase 2
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM Start of enrollment: 2020 Dec 08
Active, not recruiting
Not Applicable

Publications & Presentations

PubMed

48 citations
Single-cell analysis reveals effective siRNA delivery in brain tumors with microbubble-enhanced ultrasound and cationic nanoparticles
Yutong Guo, Hohyun Lee, Zhou Fang, Anastasia Velalopoulou, Jinhwan Kim
Science Advances. 2021-04-01
11 citations
Ligand-Gated Ion Channels as Targets for Treatment and Management of Cancers.
Rohan Rao, Sanjit Shah, Debanjan Bhattacharya, Donatien Kamdem Toukam, Román Cáceres
Frontiers in Physiology. 2022-01-01
8 citations
A Review of Approaches to Potentiate the Activity of Temozolomide against Glioblastoma to Overcome Resistance.
Aniruddha S Karve, Janki M Desai, Sidharth N Gadgil, Nimita Dave, Trisha M Wise-Draper
International Journal of Molecular Sciences. 2024-03-12

Journal Articles

Chapter 50 - Brain Cancer Genomics and Epigenomics
Soma Sengupta, Scott L Pomeroy, ScienceDirect

Authored Content

Humanizing Brain TumorsJuly 2022

Press Mentions

Integrative Medicine in Neuro-Oncology: Virtual Group VisitsOctober 2nd, 2024
Glioblastoma Studies Show PromiseJanuary 26th, 2024
Study Reveals Potential New Treatment for Patients with Metastatic MelanomaFebruary 26th, 2020
Join now to see all